Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AdvaMed Supports Splitting Up Class II Devices, But On Its Own Terms

This article was originally published in The Gray Sheet

Executive Summary

Medical device makers are sending FDA a message that while they support some formal distinctions within the broad range of Class II devices, the creation of a "Class IIb" subset goes too far

You may also be interested in...



510(k) Reform Debate: Class IIb Or Not To Be?

As FDA prepares to announce planned 510(k) program reforms in the coming weeks, a key question is what will become of the proposal to split up Class II devices into two distinct categories.

510(k) Reform Debate: Class IIb Or Not To Be?

As FDA prepares to announce planned 510(k) program reforms in the coming weeks, a key question is what will become of the proposal to split up Class II devices into two distinct categories.

Industry Takes Aim At Several Proposals In FDA's 510(k) Report

Device manufacturers are lining up against a number of FDA's proposed reforms to its 510(k) pre-market notification process, saying they could harm, not help, the agency's public health mission

Related Content

Topics

UsernamePublicRestriction

Register

MT029443

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel